• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $WVE

    Wave Life Sciences Ltd.

    Subscribe to $WVE
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials for the treatment of Huntington's disease (HD); WVE-003, mutant huntingtin SNP3 program for the treatment of HD; WVE-004, C9orf72 program for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-N531, our Exon 53 program for the treatment of Duchenne muscular dystrophy; and ATXN3 program in SCA3. The company has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, and University of Massachusetts. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

    IPO Year: 2015

    Exchange: NASDAQ

    Website: wavelifesciences.com

    Peers

    $ACHV
    $SLS
    $XNCR
    $MRVI

    Recent Analyst Ratings for Wave Life Sciences Ltd.

    DatePrice TargetRatingAnalyst
    4/29/2025$10.00Overweight
    Cantor Fitzgerald
    4/8/2025$18.00Outperform
    Wedbush
    2/25/2025$26.00Buy
    Jefferies
    10/16/2024$22.00Outperform → Strong Buy
    Raymond James
    9/27/2024$10.00 → $13.00Overweight
    JP Morgan
    9/19/2024$11.00Buy
    B. Riley Securities
    9/9/2024$10.00Overweight
    JP Morgan
    5/15/2024$11.00Overweight
    Wells Fargo
    12/19/2023$5.00 → $12.00Market Perform → Outperform
    Leerink Partners
    7/5/2023$7.00Outperform
    Raymond James
    See more ratings

    Wave Life Sciences Ltd. SEC Filings

    See more
    • SEC Form 10-Q filed by Wave Life Sciences Ltd.

      10-Q - Wave Life Sciences Ltd. (0001631574) (Filer)

      5/8/25 7:45:16 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Wave Life Sciences Ltd.

      8-K - Wave Life Sciences Ltd. (0001631574) (Filer)

      5/8/25 7:36:06 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Wave Life Sciences Ltd.

      10-K/A - Wave Life Sciences Ltd. (0001631574) (Filer)

      4/29/25 5:00:21 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events

      8-K - Wave Life Sciences Ltd. (0001631574) (Filer)

      3/26/25 7:38:33 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Wave Life Sciences Ltd.

      144 - Wave Life Sciences Ltd. (0001631574) (Subject)

      3/20/25 4:03:50 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Wave Life Sciences Ltd.

      10-K - Wave Life Sciences Ltd. (0001631574) (Filer)

      3/4/25 7:59:21 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Wave Life Sciences Ltd.

      8-K - Wave Life Sciences Ltd. (0001631574) (Filer)

      3/4/25 7:51:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Wave Life Sciences Ltd.

      SCHEDULE 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      2/14/25 4:15:03 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Ltd. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Wave Life Sciences Ltd. (0001631574) (Filer)

      1/13/25 2:00:20 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Ltd. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Wave Life Sciences Ltd. (0001631574) (Filer)

      11/20/24 6:05:04 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Wave Life Sciences Ltd. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Gsk Plc bought $22,335,440 worth of Ordinary Shares (2,791,930 units at $8.00) (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      10/1/24 5:54:39 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gsk Plc bought $16,500,000 worth of Ordinary Shares (3,300,000 units at $5.00) (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      1/30/24 4:39:08 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ra Capital Management, L.P. bought $5,000,000 worth of shares (1,000,000 units at $5.00) (SEC Form 4) (Amendment)

      4/A - Wave Life Sciences Ltd. (0001631574) (Issuer)

      1/17/24 7:06:57 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ra Capital Management, L.P. bought $5,000,000 worth of shares (1,000,000 units at $5.00) (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      12/13/23 4:33:42 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Wave Life Sciences Ltd. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

      Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort (400 mg) and multidosing (200 mg) ongoing in RestorAATion-2 clinical trial of WVE-006 in individuals with PiZZ AATD; data from the complete 200 mg multidose and single dose cohorts expected in 3Q 2025; data from complete 400 mg single dose cohort expected in the fall of 2025 Delivered positive data from FORWARD-53 clinical trial of WVE-N531 in exon 53 amenable DMD including statistically significant and clinically meaningful improvement i

      5/8/25 7:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 8, 2025, to review the company's first quarter 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call by di

      5/1/25 8:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

      Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observed in other outcome measures including NSAA First-ever demonstration of substantial improvements in muscle health with exon skipping – statistically significant reduction in fibrosis driven by decreases in inflammation and necrosis, coupled with transition from regenerative to mature muscle; decreases in creatine kinase and circulating inflammatory biomarkers Dystrophin expression stabilized between 24 and 48 weeks and averaged 7.8%, with 88% o

      3/26/25 7:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose cohort Multi-dosing ongoing in 200 mg cohort of RestorAATion-2 clinical trial of WVE-006 in AATD with data expected in 2025; second single dose cohort initiated at 400 mg On track to deliver FORWARD-53 48-week data in DMD and feedback from regulators in 1Q 2025 IND submission expected 2H 2025 for potentially registrational WVE-003 Phase 2/3 study in HD with caudate atrophy as a primary endpoint Cash and cash equivalents of $302.1 million as of December 31, 2024, with runway expected into 2027 Investor conference call and webcast at 8:30 a.m. ET today

      3/4/25 7:30:20 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

      CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, March 4, 2025, to review the company's fourth quarter and full year 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can j

      2/25/25 8:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

      WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) Proof-of-concept clinical data from INLIGHT are expected in 2025 CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced clinical trial application (CTA) approval and initiation of the Phase 1 INLIGHT clinical trial of WVE-007 in obesity. WVE-007 is a long-acting GalNAc-conjugated small interfering RNA (siRNA) that tar

      2/6/25 8:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation

      Entering 2025 having demonstrated rapid translation of genetic insights to positive clinical data; advancing clinically validated and multi-modal pipeline with the potential to treat well over 100 million patients CTAs submitted for Phase 1 INLIGHT clinical trial of WVE-007, a novel, long-acting, muscle-sparing GalNAc-siRNA approach for obesity targeting INHBE grounded in human genetics; proof-of-concept clinical data expected in 2025 Pioneering entirely new therapeutic field of RNA editing and building on positive WVE-006 proof-of mechanism clinical data; expect multidose AATD data, new preclinical data from hepatic and extra-hepatic RNA editing programs and candidate selections in 2025

      1/13/25 9:00:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

      WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twice-annual administration WVE-007 is Wave's first siRNA program to enter clinical development and uses best-in-class oligonucleotide chemistry and GalNAc delivery Wave expects to initiate the first-in-human study of WVE-007 in 1Q 2025 CAMBRIDGE, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the submission of its first clin

      12/23/24 8:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

      CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 9:45 a.m. PT / 12:45 p.m. ET. A live webcast of this presentation can be accessed by visiting "Investor Events" on the Investor Relations section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this presentation w

      12/16/24 8:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences to Present at Upcoming Investor Conferences

      CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in December. 7ᵗʰ Annual Evercore HealthCONx ConferenceDate: Tuesday, December 3, 2024Analyst-led fireside chat: 3:00 p.m. ET Citi 2024 Global Healthcare Conference Date: Wednesday, December 4, 2024"Neuromuscular Disorders" panel: 1:00 p.m. ET Live webcasts of these presentations can be accessed by visiting "Investor Events" on

      11/26/24 8:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Wave Life Sciences Ltd. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    Wave Life Sciences Ltd. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Wave Life Sciences with a new price target

      Cantor Fitzgerald initiated coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $10.00

      4/29/25 8:13:21 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Wave Life Sciences with a new price target

      Wedbush initiated coverage of Wave Life Sciences with a rating of Outperform and set a new price target of $18.00

      4/8/25 9:33:34 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Wave Life Sciences with a new price target

      Jefferies initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $26.00

      2/25/25 7:15:48 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences upgraded by Raymond James with a new price target

      Raymond James upgraded Wave Life Sciences from Outperform to Strong Buy and set a new price target of $22.00

      10/16/24 1:07:15 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan resumed coverage on Wave Life Sciences with a new price target

      JP Morgan resumed coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $13.00 from $10.00 previously

      9/27/24 7:45:18 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities initiated coverage on Wave Life Sciences with a new price target

      B. Riley Securities initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $11.00

      9/19/24 7:54:52 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan initiated coverage on Wave Life Sciences with a new price target

      JP Morgan initiated coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $10.00

      9/9/24 7:52:31 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Wave Life Sciences with a new price target

      Wells Fargo initiated coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $11.00

      5/15/24 7:42:44 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Wave Life Sciences from Market Perform to Outperform and set a new price target of $12.00 from $5.00 previously

      12/19/23 7:41:08 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James initiated coverage on Wave Life Sciences with a new price target

      Raymond James initiated coverage of Wave Life Sciences with a rating of Outperform and set a new price target of $7.00

      7/5/23 8:13:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Henry Christian O sold $102,574 worth of Ordinary Shares (10,500 units at $9.77) and exercised 10,500 units of Ordinary Shares at a strike of $9.13 (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      3/21/25 9:00:05 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Bolno Paul exercised 169,025 units of Ordinary Shares at a strike of $2.48 and sold $1,617,569 worth of Ordinary Shares (169,025 units at $9.57) (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      3/7/25 9:05:03 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Verdine Gregory L. exercised 266,402 units of Ordinary Shares at a strike of $2.48, increasing direct ownership by 577% to 312,517 units (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      3/7/25 9:00:05 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Vargeese Chandra exercised 91,754 units of Ordinary Shares at a strike of $2.48, increasing direct ownership by 34% to 362,687 units (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      3/5/25 5:14:26 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Moran Kyle was granted 42,000 units of Ordinary Shares, increasing direct ownership by 89% to 89,218 units (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      2/6/25 8:00:09 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Francis Chris was granted 25,000 units of Ordinary Shares (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      2/6/25 8:00:06 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Bolno Paul was granted 121,000 units of Ordinary Shares, increasing direct ownership by 56% to 338,351 units (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      2/6/25 8:00:07 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Vargeese Chandra was granted 37,000 units of Ordinary Shares, increasing direct ownership by 16% to 270,933 units (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      2/6/25 8:00:04 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Vargeese Chandra exercised 46,000 units of Ordinary Shares at a strike of $2.48, increasing direct ownership by 24% to 233,933 units (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      1/24/25 5:30:03 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Bolno Paul sold $750,000 worth of Ordinary Shares (50,000 units at $15.00) and exercised 50,000 units of Ordinary Shares at a strike of $2.48 (SEC Form 4)

      4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

      11/27/24 9:00:09 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Wave Life Sciences Ltd. Leadership Updates

    Live Leadership Updates

    See more
    • Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

      CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer. Dr. Ingelsson will drive Wave's emerging therapeutic portfolio strategy, including growing its genetics and genomics capabilities for identifying new, high impact targets, and leveraging the company's best-in-class multimodal discovery and development platform to advance transformative RNA medicines. Most recently, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery, at GSK

      5/9/24 7:00:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors

      BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Michael A. Panzara, M.D., MPH to its Board of Directors. Dr. Panzara currently serves as Chief Medical Officer, Head of Therapeutics Discovery and Development at Wave Life Sciences (NASDAQ:WVE) and brings over 20 years of biopharmaceutical industry experience developing therapies for neurological disorders, including in leadership roles at Sanofi Genzyme and Biogen. "Mike is a recognized and experienced leader in the development

      3/21/22 7:05:00 AM ET
      $ATHA
      $WVE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Wave Life Sciences Announces Appointment of Jonathan Rosin as Chief Human Resources Officer

      CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Jonathan Rosin has been appointed as Chief Human Resources Officer (CHRO). As CHRO, Mr. Rosin will provide strategic enterprise counsel and leadership, both as a member of Wave’s Executive Team and by leading the human resources function. “Jonathan is an accomplished leader with the breadth of human resources experience necessary to help guide Wave as we prepare to support five programs in clinical trials in 2021, as well as advance a robust precl

      12/2/20 8:00:00 AM ET
      $SNY
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Wave Life Sciences Ltd. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

      SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      11/12/24 4:30:35 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

      SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      11/12/24 9:34:18 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Wave Life Sciences Ltd.

      SC 13D/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      10/1/24 5:47:15 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Wave Life Sciences Ltd. (Amendment)

      SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      2/14/24 5:02:01 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Wave Life Sciences Ltd. (Amendment)

      SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      2/14/24 4:02:36 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Wave Life Sciences Ltd. (Amendment)

      SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      2/13/24 10:13:56 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Wave Life Sciences Ltd. (Amendment)

      SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      2/12/24 4:15:31 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Wave Life Sciences Ltd. (Amendment)

      SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      2/7/24 8:03:31 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Wave Life Sciences Ltd. (Amendment)

      SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      2/6/24 5:07:42 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Wave Life Sciences Ltd. (Amendment)

      SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

      2/14/23 4:08:05 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Wave Life Sciences Ltd. Financials

    Live finance-specific insights

    See more
    • Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

      Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort (400 mg) and multidosing (200 mg) ongoing in RestorAATion-2 clinical trial of WVE-006 in individuals with PiZZ AATD; data from the complete 200 mg multidose and single dose cohorts expected in 3Q 2025; data from complete 400 mg single dose cohort expected in the fall of 2025 Delivered positive data from FORWARD-53 clinical trial of WVE-N531 in exon 53 amenable DMD including statistically significant and clinically meaningful improvement i

      5/8/25 7:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 8, 2025, to review the company's first quarter 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call by di

      5/1/25 8:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

      Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observed in other outcome measures including NSAA First-ever demonstration of substantial improvements in muscle health with exon skipping – statistically significant reduction in fibrosis driven by decreases in inflammation and necrosis, coupled with transition from regenerative to mature muscle; decreases in creatine kinase and circulating inflammatory biomarkers Dystrophin expression stabilized between 24 and 48 weeks and averaged 7.8%, with 88% o

      3/26/25 7:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose cohort Multi-dosing ongoing in 200 mg cohort of RestorAATion-2 clinical trial of WVE-006 in AATD with data expected in 2025; second single dose cohort initiated at 400 mg On track to deliver FORWARD-53 48-week data in DMD and feedback from regulators in 1Q 2025 IND submission expected 2H 2025 for potentially registrational WVE-003 Phase 2/3 study in HD with caudate atrophy as a primary endpoint Cash and cash equivalents of $302.1 million as of December 31, 2024, with runway expected into 2027 Investor conference call and webcast at 8:30 a.m. ET today

      3/4/25 7:30:20 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

      CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, March 4, 2025, to review the company's fourth quarter and full year 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can j

      2/25/25 8:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

      Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced three wholly owned GalNAc-AIMer preclinical programs that offer first-in-class approaches to address unmet needs in cardiometabolic diseases WVE-007 (INHBE GalNAc-siRNA) clinical trial on track for 1Q 2025; preclinical data demonstrates opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s Received supportive initial feedback from FDA on WVE-003; FDA is engaged in discussing pathways to accelerated approval and open to Wave's plan to evaluate biomarkers, in

      11/12/24 7:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024

      CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, November 12, 2024, to review the company's third quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference

      11/4/24 4:05:00 PM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

      Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, in a prespecified analysis; dystrophin was comprised of two isoforms consistent with Becker muscular dystrophy patients who display milder disease Data demonstrated meaningful improvement in serum biomarkers for muscle health, with localization of WVE-N531 in myogenic stem cells and regeneration of myofibers Skeletal muscle concentrations of ~41,000 ng/g combined with 61-day tissue half-life support monthly dosing going forward; preclinical data suggest participants may have even higher concentrations in heart and diaphragm WVE-N531 was safe and well tol

      9/24/24 7:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

      Successful clinical translation of Wave's RNA medicines platform in HD patients with WVE-003 provides further validation of Wave's proprietary platform with PN and stereochemistry; opt-in package for WVE-003 submitted to partner Takeda and engagement with regulators initiated to discuss potential path to accelerated approval Dystrophin data on track for 3Q 2024 from potentially registrational FORWARD-53 trial of WVE-N531, which has previously demonstrated industry-leading exon skipping of 53%; positive data would unlock a best-in-class functional dystrophin franchise for DMD Dosing initiated in 3Q 2024 in RestorAATion-2 clinical trial of WVE-006 in AATD patients; proof-of-mechanism da

      8/8/24 7:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024

      CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 8, 2024, to review the company's second quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call at the f

      8/1/24 8:30:00 AM ET
      $WVE
      Biotechnology: Pharmaceutical Preparations
      Health Care